Fig. 3From: Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancerSubgroup analysis for progression-free survival in patients receiving surgery with R0 versus chemotherapy alone. Federation of Gynecology and Obstetrics, FIGO; primary debulking surgery, PDS; neoadjuvant chemotherapy followed by interval debulking surgery, NACT-IDSBack to article page